Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Fuzuloparib in Relapsed SCLC
NCT04041011Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of adebrelimab and fluzoparib in small cell lung cancer (SCLC) (3 arms), sponsored by Hengrui. Primary endpoints: Number of Participants with AEs and SAEs up to 24 months, Recommended dose for phase II study up to 24 months and 1 more. Started Sep 2019; status: completed.
02
Drugs
adebrelimabfluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04041011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041011.